Bayer, Mammoth Biosciences to team up for novel gene editing tech
Category: #headlines  By Nikita Chaurasia  Date: 2022-01-11
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Bayer, Mammoth Biosciences to team up for novel gene editing tech

Pharmaceutical and life sciences company Bayer AG has reportedly entered into a strategic collaboration and option agreement with Mammoth Biosciences Inc., a company that is harnessing nature's diversity to power novel CRISPR products, to use Mammoth’s CRISPR systems for creating in vivo gene-editing therapies.

Developed by Mammoth Biosciences, the revolutionary gene-editing technology is both a crucial enabler and a stand-alone therapeutic approach. It will help Bayer accelerate the development of breakthrough therapies for patients while also bolstering the company's newly developed cell and gene therapy platform. As per the agreement, the two businesses will begin their collaboration by focusing on liver-targeted disorders.

Notably, the development of cell and gene therapies is the next major step in the drug development field. They may be capable of permanently curing diseases with a one-time treatment by addressing the fundamental cause of disorders.

When used outside the living body (ex vivo), gene editing is a crucial enabler for cell treatments, and when used inside the living body, it enables therapeutic targeting of a variety of genetic illnesses with a high unmet medical need (in vivo).

The exclusive toolset of ultra-small Cas enzymes developed by Mammoth Biosciences, including Cas14 and Cas, enables high-fidelity gene editing to be paired with targeted systemic administration. Bayer now has access to this innovative gene-editing technology, which has the potential for increased in vivo applicability owing to the ultra-compact size of these innovative CRISPR systems.

Mammoth Biosciences will be paid around USD 40 million in advance and will be eligible for target option exercise fees and potential future payments in the amount of more than USD 1 billion after certain research & development, as well as commercial landmarks are achieved across 5 preselected in vivo indications, with a primary emphasis on liver-targeted diseases, as per the terms of the agreement.

Bayer will also provide research funds and tiered royalties up to a low double-digit percentage of net sales. On a nonexclusive basis, the companies are also looking to work on ex vivo projects.

Source Credits: https://www.businesswire.com/news/home/20220109005059/en/Bayer-and-Mammoth-Biosciences-to-Collaborate-on-Novel-Gene-Editing-Technology

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.S. airline CEOs forewarn against potential effects of 5G on planes

U.S. airline CEOs forewarn against potential effects of 5G on planes

By Nikita Chaurasia

The chief executive officers of major U.S. cargo and passenger carriers warned of a possibly ‘catastrophic’ disruption in the aviation industry that might begin once Verizon and AT&T deploy their new 5G service. The airlines said tha...

U.K. govt to cut BBC funding, caps viewer fees over inflation concerns

U.K. govt to cut BBC funding, caps viewer fees over inflation concerns

By Nikita Chaurasia

The British government is reportedly planning to curtail funding for the British Broadcasting Corporation (BBC), by putting a cap on the fees paid by viewers to watch the broadcasting channel for two years. According to reports, the inflation rate i...

Gmail becomes Google’s fourth app to exceed 10 billion installations

Gmail becomes Google’s fourth app to exceed 10 billion installations

By Nikita Chaurasia

The Google Play Services app, Google Maps, and YouTube are the other Google apps to achieve this milestone. Gmail was introduced back in 2004 and has since been integrated with various new features. Sources with relevant information stated that...